Literature DB >> 28124441

Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.

Pierre Sohier1, Armelle Luscan2,3, Angharad Lloyd4, Kevin Ashelford4, Ingrid Laurendeau3, Audrey Briand-Suleau2,3, Dominique Vidaud2,3, Nicolas Ortonne5, Eric Pasmant2,3, Meena Upadhyaya4.   

Abstract

The commonest tumors associated with neurofibromatosis type 1 (NF1) are benign peripheral nerve sheath tumors, called neurofibromas. Malignant transformation of neurofibromas into aggressive MPNSTs may occur with a poor patient prognosis. A cooperative role of SUZ12 or EED inactivation, along with NF1, TP53, and CDKN2A loss-of-function, has been proposed to drive progression to MPNSTs. An exome sequencing analysis of eight MPNSTs, one plexiform neurofibroma, and seven cutaneous neurofibromas was undertaken. Biallelic inactivation of the NF1 gene was observed in the plexiform neurofibroma and the MPNSTs, underlining that somatic biallelic NF1 inactivation is likely to be the initiating event for plexiform neurofibroma genesis, although it is unlikely to be sufficient for the subsequent MPNST development. The majority (5/8) of MPNSTs in our analyses demonstrated homozygous or heterozygous deletions of CDKN2A, which may represent an early event following NF1 LOH in the malignant transformation of Schwann cells from plexiform neurofibroma to MPNST. Biallelic somatic alterations of SUZ12 was also found in 4/8 MPNSTs. EED biallelic alterations were detected in 2 of the other four MPNSTs, with one tumor having a homozygous EED deletion. A missense mutation in the chromatin regulator KDM2B was also identified in one MPNST. No TP53 point mutations were found in this study, confirming previous data that TP53 mutations may be relatively rare in NF1-associated MPNSTs. Our study confirms the frequent biallelic inactivation of PRC2 subunits SUZ12 and EED in MPNSTs, and suggests the implication of KDM2B.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28124441     DOI: 10.1002/gcc.22446

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

1.  Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.

Authors:  John B Wojcik; Dylan M Marchione; Simone Sidoli; Anissa Djedid; Amanda Lisby; Jacek Majewski; Benjamin A Garcia
Journal:  Cancer Res       Date:  2019-03-21       Impact factor: 12.701

Review 2.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

3.  Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.

Authors:  Cleofe Romagosa; Eduard Serra; Bernat Gel; Miriam Magallón-Lorenz; Juana Fernández-Rodríguez; Ernest Terribas; Edgar Creus-Batchiller; Anna Estival; Diana Perez Sidelnikova; Héctor Salvador; Alberto Villanueva; Ignacio Blanco; Meritxell Carrió; Conxi Lázaro
Journal:  Hum Genet       Date:  2021-05-31       Impact factor: 4.132

4.  Computational insights of K1444N substitution in GAP-related domain of NF1 gene associated with neurofibromatosis type 1 disease: a molecular modeling and dynamics approach.

Authors:  Ashish Kumar Agrahari; Meghana Muskan; C George Priya Doss; R Siva; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2018-05-27       Impact factor: 3.584

5.  EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Authors:  Michel Wassef; Armelle Luscan; Setareh Aflaki; Dina Zielinski; Pascal W T C Jansen; H Irem Baymaz; Aude Battistella; Carole Kersouani; Nicolas Servant; Margaret R Wallace; Pierre Romero; Olivier Kosmider; Pierre-Alexandre Just; Mikaël Hivelin; Sébastien Jacques; Anne Vincent-Salomon; Michiel Vermeulen; Michel Vidaud; Eric Pasmant; Raphaël Margueron
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

Review 6.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

7.  A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.

Authors:  Juana Fernández-Rodríguez; Edgar Creus-Bachiller; Xiaohu Zhang; Maria Martínez-Iniesta; Sara Ortega-Bertran; Rajarshi Guha; Craig J Thomas; Margaret R Wallace; Cleofe Romagosa; Lourdes Salazar-Huayna; Karlyne M Reilly; Jaishri O Blakely; Jordi Serra-Musach; Miguel Angel Pujana; Eduard Serra; Alberto Villanueva; Marc Ferrer; Conxi Lázaro
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

8.  WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.

Authors:  Craig S Thomson; Jay Pundavela; Melissa R Perrino; Robert A Coover; Kwangmin Choi; Katherine E Chaney; Tilat A Rizvi; David A Largaespada; Nancy Ratner
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

9.  Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.

Authors:  Chetan Bettegowda; Meena Upadhayaya; D Gareth Evans; AeRang Kim; Dimitrios Mathios; Clemens O Hanemann
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

10.  Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.

Authors:  Gabrielle Karpinsky; Malgorzata A Krawczyk; Ewa Izycka-Swieszewska; Aleksandra Fatyga; Agnieszka Budka; Walentyna Balwierz; Grazyna Sobol; Beata Zalewska-Szewczyk; Magdalena Rychlowska-Pruszynska; Teresa Klepacka; Bozenna Dembowska-Baginska; Bernarda Kazanowska; Anna Gabrych; Ewa Bien
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-13       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.